

Date: May 29, 2024

To,
Corporate Relationship Department,
BSE Limited
PJ Towers, Dalal Street,
Mumbai 400001, MH

Stock Code: 542248

Subject: Press Release

Dear Sir/Madam,

This is further to our letter of the date intimating the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2024, enclosed is a copy of the Press Release on the same for your records.

The above information is being hosted on the Company's website www.deccanhealthcare.co.in in terms of Regulation 46 of the Listing Regulations, as amended.

You are requested to take the same on record.

Thanking You,
For and on behalf of
Deccan Health Care Limited


Vaishali Gagnani
Company Secretary & Compliance Officer
Encl: a/a

Registered office:

CIN: L72200TG1996PLC024351. Estd: 1996
Address : H.No. 6-3-348/4, Dwarkapuri
Colony, Punjagutta, Hyderabad,
Telangana-500082

Innovation Hub & manufacturing:

Address: Plot No.13, Sector-03, (SIDCUL), IIE,
Panthnagar, Udam Singh Nagar
-263153,U.K., India

**Deccan Health Care Limited Reports a 33% YoY Revenue Growth for FY24,
Accompanied by a 3.8x Increase in PAT (YoY)**

Hyderabad, 29th May 2024: Deccan Healthcare Limited (BSE: 542248), a leading nutraceuticals product company, with an aim to help consumers age gracefully, reduce the risk of disease, prevent disease, and live a better quality of life, today announced its audited financial results for the Q4 & FY24 period which ended 31st March 2024.

Key Business Highlights:

- ▷ **Expansion into NutriFoods:** Leveraging CSIR IHBT's advanced technology, our company has successfully ventured into the NutriFoods sector.
- ▷ **Successful Product Launches:**
 - **OrganoWild Millet Cookies:** Introduced in December 2023, these cookies have received strong consumer acceptance, prompting a regional expansion of distribution.
 - **OrganoWild Natural Iron Mango Slice:** Launched in May 2024, this unique product boosts daily dietary iron intake and aids in the prevention and prophylaxis of anemia, particularly in adolescents and women of reproductive age.
- ▷ **Anemia Mukht Bharat Program Participation:**
 - Supplied resources and Iron Mango Bars to 600 girls at Telangana school, resulting in improved health and increased haemoglobin levels.
 - Expanding collaboration with NGOs to support the Anemia Mukht Bharat initiative of the Government of India.
- ▷ **Strategic Investment:** We're pleased to announce the establishment of our subsidiary, DBL USA, to distribute our products across the USA, Canada, and South America markets. This initiative will require a total investment of \$5 million in a phased manner.
- ▷ **International Expansion:** Pursuing product registration to facilitate exports to GCC countries, marking our entry into new international markets.

Standalone Financial Performance for Q4 & FY24 (₹ in Lakh):

Parameters	Q4FY24	Q3FY24	QoQ	Q4FY23	YoY	FY24	FY23	YoY
Revenue	1,596.8	1,534.3	4.1%	1,585.9	0.7%	5,972.9	4,502.2	32.7%
EBITDA	67.0	123.5	(45.8)%	79.5	(15.7)%	375.9	205.6	82.8%
EBITDA Margin	4.2%	8.1%	(386) bps	5.0%	(82) bps	6.3%	4.6%	+173 bps
PAT	12.8	55.1	(76.7)%	31.1	(58.7)%	152.2	39.7	3.8x
PAT Margin	0.8%	3.6%	(279) bps	2.0%	(116) bps	2.5%	0.9%	+166 bps

Commenting on the results, Dr. Minto Purshotam Gupta, Chairman & Managing Director of Deccan Healthcare Limited said, “We are happy to announce that our launch of OrganoWild in the NutriFoods segment is gaining momentum, and we are excited about our company's progress in leveraging the innovative know-how and technology developed by CSIR IHBT. Since introducing our OrganoWild Millet Cookies in December 2023, we have received strong consumer acceptance, prompting us to expand our distribution regionally.

In May, we launched our unique Organowild Natural Iron Mango Slice, the first product designed to boost daily dietary iron intake and aid in preventing and managing anemia, particularly among adolescents and women of reproductive age. Our participation in the Anemia Mukh Bharat program exemplifies our commitment to health and wellness. We are expanding our involvement in various initiatives by collaborating with different marketing channels to further support the program's goals.

For the full year, the company experienced strong annual growth in revenue, gross profit, EBITDA, and PAT for FY24 compared to FY23, reflecting our potential for continued growth in the coming years. Additionally, we are executing our strategy to cater to international markets by establishing our subsidiary, DBL USA, to distribute our products across the USA, Canada, and South America markets. This initiative will require a total investment of \$5 million in a phased manner. We are also pursuing product registration to facilitate exports to the GCC countries, marking our entry into new international markets. As we expand our products and enter new markets, we are committed to delivering strong financial performance and enhancing shareholder value. Together, we look forward to sustained growth and innovation.”

About Deccan Healthcare Limited (BSE: 542248):

Deccan Healthcare Limited, established in 1996, is a leading nutraceutical company committed to helping consumers age gracefully and enhance their overall well-being. With a focus on innovation, supply chains, and brand equity, the company consistently delivers superior value to its customers. Popular for its Fast-Moving Consumer Healthcare products, including food pills and meals, Deccan Healthcare Limited addresses 52+ wellness goals, preventing over 200+ diseases. The success of the BE YOUNG brand, particularly through e-commerce, reflects the company's dedication. Moreover, the international expansion with the STAY YOUNG brand further demonstrates its dynamic approach. Deccan Healthcare Limited stands out as a positive force in the nutraceuticals industry, prioritizing consumer health and sustained growth.

Safe Harbor:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential, and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

DECCAN HEALTHCARE LIMITED CIN: L72200TG1996PLC024351	
Dr. Minto Purshotam Gupta Chairman & Managing Director E: cmd@deccanhealthcare.co.in W: www.deccanhealthcare.co.in	Mr. Ritesh Shashiprakash Singh Investor Relations Consultant, Rik Capital M: +91 83293 85762 E: ritesh.singh@rikcapital.in W: www.rikcapital.in